A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive
Yoshinobu Hata, MD, PhD
Advertisement
Articles by Yoshinobu Hata, MD, PhD
Advertisement
Latest Updated Articles
- UFT and Mitomycin Plus Tamoxifen for Stage II, ER-Positive Breast Cancer
Published: July 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Sevabertinib in Non-Squamous NSCLC
2
Tarlatamab Earns Traditional FDA Approval in ES-SCLC
3
FDA OKs Selumetinib in NF1 Symptomatic, Inoperable Plexiform Neurofibromas
4
FDA Traditionally Approves Daratumumab Regimen in AL Amyloidosis
5
